New research reveals that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt conventional diet and exercise regimens.
Published data in a prominent medical journal points out that while overweight individuals often shed a large proportion of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such medications should be aware of the potential of fast weight regain when the therapy is stopped," stated expert Dr. Susan Jebb.
Such speed of regain means a reversion to original weight within about a year and a half.
Comparing Therapies
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers note that people who lose weight through dieting typically experience a less rapid weight regain—around 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the amplified weight return.
The injections copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Condition?
Medical guidelines advise the injections for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals argue that, considering the significant potential of weight regain, the therapy is often long-term.
This perspective is supported by pharmaceutical companies, who note that the results "underscore the persistent character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Individuals who have discontinued the jabs explain a powerful return of hunger.
"It felt as if a trigger activating and you become extremely hungry," recalled an individual.
This difficulty is worsened if patients have not developed permanent lifestyle or habit changes during treatment.
Growing Use
Figures indicate that millions of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is greater among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a permanent cure and lasting health benefits likely depends on ongoing lifestyle management.
